Market Cap 4.76B
Revenue (ttm) 37.31M
Net Income (ttm) -366.25M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -981.64%
Debt to Equity Ratio 0.00
Volume 1,386,100
Avg Vol 1,792,684
Day's Range N/A - N/A
Shares Out 95.30M
Stochastic %K 25%
Beta 1.70
Analysts Strong Sell
Price Target $82.38

Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR...

Industry: Biotechnology
Sector: Healthcare
Phone: 41 41 561 32 77
Address:
Baarerstrasse 14, Zug, Switzerland
george4it
george4it Feb. 4 at 12:31 AM
$CRSP Picked a few shares of this today at 51. Might have a surprise move to the upside soon.
0 · Reply
svertical1
svertical1 Feb. 3 at 8:53 PM
$CRSP Years of expectations….. https://x.com/rainmaker1973/status/2018673342178304262?s=42
0 · Reply
Elamenape2
Elamenape2 Feb. 3 at 7:58 PM
$PRME $BEAM $NTLA $CRSP Rare Pediatric Disease PRV Program Reauthorized by Congress! After a two-year campaign to reauthorize the Rare Pediatric Disease Priority Review Voucher (PRV) Program, the rare disease community's relentless advocacy has paid off. https://abcnews.go.com/Politics/house-hold-votes-funding-end-partial-government-shutdown/story?id=129813498
0 · Reply
Maestroshira
Maestroshira Feb. 3 at 7:48 PM
$CRSP back to $70
0 · Reply
BobJohnBuoy666
BobJohnBuoy666 Feb. 3 at 6:25 PM
$CRSP adding
0 · Reply
BullYa
BullYa Feb. 3 at 3:55 PM
$CRSP ✅ buy! Stock should be in $60’s
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Feb. 3 at 2:44 PM
$INBS : Redefining the Future of Drug Screening Intelligent Bio Solutions is a diagnostics technology company advancing drug testing with a proprietary, non-invasive fingerprint sweat analysis platform, delivering fast, hygienic results as an alternative to traditional urine and saliva testing. 📈 Recent Milestones & Key Catalysts: INBS continues to execute on its growth strategy with several notable developments: 🥇FDA 510(k) submission, positioning the company for entry into the U.S. market 🥈Expansion of manufacturing capacity through a strategic global partner, improving scalability and margins 🥉Latest company update reporting approximately $13.78M in total assets versus $5.45M in total liabilities ➡️A growing commercial footprint with over 450 customers across 24 countries ➡️Ongoing innovation initiatives aimed at expanding non-invasive biosensing applications Communicated Disclaimer: http://stockresearchtoday.com/transforming-d… Sector Peers: $MRNA $CRSP $GILD $CDMO
0 · Reply
ParagonStar1
ParagonStar1 Feb. 3 at 2:26 PM
$CRSP Pt 60$+
0 · Reply
ZacksResearch
ZacksResearch Feb. 3 at 1:34 PM
$CRSP earnings are coming — and the setup looks compelling. 👀 CRISPR Therapeutics heads into Q4 with rising Casgevy sales, collaboration revenues from Vertex, and a track record of beating estimates — a combo that has investors paying attention. Is another earnings beat in the cards? Full preview here 👉 https://www.zacks.com/stock/news/2827639/crsp-to-report-q4-earnings-is-a-beat-in-store-for-the-stock?cid=sm-stocktwits-2-2827639-teaser-31604&ADID=SYND_STOCKTWITS_TWEET_2_2827639_TEASER_31604
0 · Reply
Zenline_
Zenline_ Feb. 3 at 1:18 PM
$CRSP Risk/reward shifts if volume expands, keeping an eye on breakout potential
0 · Reply
Latest News on CRSP
Crispr Therapeutics: Patience And Opportunity Through Volatility

Jan 14, 2026, 11:30 AM EST - 20 days ago

Crispr Therapeutics: Patience And Opportunity Through Volatility


The Big 3: ASML, GOOGL, CRSP

Jul 15, 2025, 12:01 PM EDT - 7 months ago

The Big 3: ASML, GOOGL, CRSP

ASML GOOG GOOGL


The Big 3: CRSP, OKLO, GME

Jun 23, 2025, 12:01 PM EDT - 8 months ago

The Big 3: CRSP, OKLO, GME

OKLO GME


Crispr Therapeutics: Betting On A One-Shot Future

Jun 13, 2025, 6:27 PM EDT - 8 months ago

Crispr Therapeutics: Betting On A One-Shot Future


CRISPR Therapeutics Set To Reach Previous Heights

Mar 25, 2025, 11:03 AM EDT - 11 months ago

CRISPR Therapeutics Set To Reach Previous Heights


george4it
george4it Feb. 4 at 12:31 AM
$CRSP Picked a few shares of this today at 51. Might have a surprise move to the upside soon.
0 · Reply
svertical1
svertical1 Feb. 3 at 8:53 PM
$CRSP Years of expectations….. https://x.com/rainmaker1973/status/2018673342178304262?s=42
0 · Reply
Elamenape2
Elamenape2 Feb. 3 at 7:58 PM
$PRME $BEAM $NTLA $CRSP Rare Pediatric Disease PRV Program Reauthorized by Congress! After a two-year campaign to reauthorize the Rare Pediatric Disease Priority Review Voucher (PRV) Program, the rare disease community's relentless advocacy has paid off. https://abcnews.go.com/Politics/house-hold-votes-funding-end-partial-government-shutdown/story?id=129813498
0 · Reply
Maestroshira
Maestroshira Feb. 3 at 7:48 PM
$CRSP back to $70
0 · Reply
BobJohnBuoy666
BobJohnBuoy666 Feb. 3 at 6:25 PM
$CRSP adding
0 · Reply
BullYa
BullYa Feb. 3 at 3:55 PM
$CRSP ✅ buy! Stock should be in $60’s
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Feb. 3 at 2:44 PM
$INBS : Redefining the Future of Drug Screening Intelligent Bio Solutions is a diagnostics technology company advancing drug testing with a proprietary, non-invasive fingerprint sweat analysis platform, delivering fast, hygienic results as an alternative to traditional urine and saliva testing. 📈 Recent Milestones & Key Catalysts: INBS continues to execute on its growth strategy with several notable developments: 🥇FDA 510(k) submission, positioning the company for entry into the U.S. market 🥈Expansion of manufacturing capacity through a strategic global partner, improving scalability and margins 🥉Latest company update reporting approximately $13.78M in total assets versus $5.45M in total liabilities ➡️A growing commercial footprint with over 450 customers across 24 countries ➡️Ongoing innovation initiatives aimed at expanding non-invasive biosensing applications Communicated Disclaimer: http://stockresearchtoday.com/transforming-d… Sector Peers: $MRNA $CRSP $GILD $CDMO
0 · Reply
ParagonStar1
ParagonStar1 Feb. 3 at 2:26 PM
$CRSP Pt 60$+
0 · Reply
ZacksResearch
ZacksResearch Feb. 3 at 1:34 PM
$CRSP earnings are coming — and the setup looks compelling. 👀 CRISPR Therapeutics heads into Q4 with rising Casgevy sales, collaboration revenues from Vertex, and a track record of beating estimates — a combo that has investors paying attention. Is another earnings beat in the cards? Full preview here 👉 https://www.zacks.com/stock/news/2827639/crsp-to-report-q4-earnings-is-a-beat-in-store-for-the-stock?cid=sm-stocktwits-2-2827639-teaser-31604&ADID=SYND_STOCKTWITS_TWEET_2_2827639_TEASER_31604
0 · Reply
Zenline_
Zenline_ Feb. 3 at 1:18 PM
$CRSP Risk/reward shifts if volume expands, keeping an eye on breakout potential
0 · Reply
ZacksResearch
ZacksResearch Feb. 3 at 12:34 PM
$CRSP set to beat earnings expectations! 🚀 With an impressive +15.85% Earnings ESP and a Zacks Rank #3, CRISPR Therapeutics is positioned for a strong report. 📈 Their approved gene therapy, Casgevy, is improving collaboration expenses and supporting their bottom line. Discover the full analysis here 👉 https://www.zacks.com/stock/news/2827639/crsp-to-report-q4-earnings-is-a-beat-in-store-for-the-stock?cid=sm-stocktwits-2-2827639-body-31603&ADID=SYND_STOCKTWITS_TWEET_2_2827639_BODY_31603
0 · Reply
StockBarG
StockBarG Feb. 3 at 7:18 AM
$CRSP I’ve been waiting forever for it to dip below $50 – in at $49.55
0 · Reply
GreyBeard43
GreyBeard43 Feb. 3 at 3:28 AM
$CRSP the downside here looks to be in the 30s. The upside seems to be much higher. Not financial 🤮
0 · Reply
BullYa
BullYa Feb. 2 at 7:11 PM
$CRSP still so underpriced stock. Buy! It should be in 60~65$ at normally range ✅
1 · Reply
Enjoy_Life_Bro
Enjoy_Life_Bro Feb. 2 at 6:40 PM
$CRSP Let’s go
0 · Reply
Maestroshira
Maestroshira Feb. 2 at 6:39 PM
$CRSP back to $60
0 · Reply
Save4theFuture
Save4theFuture Feb. 2 at 4:32 PM
$CRSP lets go back to $60
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 2 at 4:02 PM
$CRSP Share Price: $50.94 Contract Selected: Feb 27, 2026 $49.0 Calls Buy Zone: $2.12 – $2.62 Target Zone: $3.48 – $4.26 Potential Upside: 55% ROI Time to Expiration: 24 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Wallear
Wallear Feb. 2 at 3:13 PM
$CRSP vrtx earnings on February 12 will give us a strong uptick in patient referrals. And maybe some news will come at the Guggenhiem, assuming that CRSP attends. We need Casgevy sales and strong phase 2 results and we will have both by the EOY
0 · Reply
Etrading
Etrading Feb. 2 at 2:29 PM
$CRSP lol pay me at open:) told you short at 61 pump last week lol
0 · Reply
handmedown1
handmedown1 Feb. 2 at 2:21 PM
$CRSP simeone wont stand for this
0 · Reply
dens214
dens214 Feb. 2 at 3:44 AM
$CRSP What is wrong with Crsp? 2 yrs since fda approval, well capitalised. Stock performance stinks. So what is the solution.
0 · Reply